Table 1.

FDA approved PARP inhibitors for clinical use and associated indications

PARP inhibitor	Clinical indications
Olaparib	Maintenance therapy for platinum sensitive, recurrent, BRCA mutated ovarian cancer after ≥ 3 prior chemo regimens Maintenance therapy for platinum sensitive, recurrent, epithelial ovarian, fallopian, and peritoneal cancer with confirmed or suspected BRCA mutations Treatment of metastatic, HER2 negative, BRCA mutated breast cancer who previously received chemotherapy Treatment of metastatic, BRCA mutated, pancreatic cancer
Rucaparib	Treatment of platinum sensitive, recurrent ovarian, fallopian, and peritoneal cancer
Niraparib	Maintenance therapy for platinum sensitive, recurrent ovarian, fallopian, and peritoneal cancer
Talazoparib	Treatment of BRCA mutated, HER2 negative, advanced breast cancer